Importantly, genetic and pharmacological destruction of GSK3B-mediated T334 phosphorylation leads to HR repair deficiency and makes cancer cells susceptible to synthetic lethality of PARPi therapy independent of BRCA1 status. The gene discussed is GSK3B; the disease is cancer.